Conclusions
neurotoxic
PATHOPHYSIOLOGY
Study AB09004 represents the first successful randomized, controlled, phase 3 trial in AD of a tyrosine kinase inhibitor, targeting innate immune cells. Given the known targets of masitinib, these positive clinical findings suggest that mast cells and/or macrophage/microglia are implicated in the pathophysiology of mild-to-moderate AD, possibly by switching the neuroimmune system from a neurotoxic state towards a neuroprotective state through remodeling of the neuronal microenvironment [In the absence of a consensus regarding the minimal clinically important change for ADAS-Cog [